Physician profile
Preethi Sridhar
NPI 1033362041
$7,339.79
in general payments reported to CMS, 2019-2025
41 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $102 · 2021: $137 · 2022: $1,367 · 2023: $1,204 · 2024: $2,039 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,971.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,199.13 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.72 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $813.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $657.57 | 2019-2025 | Evenity, Prolia, Prolia |
| Radius Health, INC. | $473.47 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $312.52 | 2019-2025 | |
| Abbott Laboratories | $311.69 | 2021-2025 | Freestyle Libre 3 |
| Madrigal Pharmaceuticals | $255.03 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $253.74 | 2024 | Ilet Bionic Pancreas |
| Abbvie INC. | $237.71 | 2019-2025 | Synthroid |
| Mannkind Corporation | $235.66 | 2019-2025 | Afrezza |
| Dexcom, INC. | $226.95 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $182.37 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $140.12 | 2019-2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $129.73 | 2022-2025 | Gvoke Hypopen |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $99.00 | 2022-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $89.72 | 2019-2022 | |
| Kyowa Kirin, INC. | $77.50 | 2024-2025 | Crysvita |
| Embecta Corp. | $70.71 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Shire North American Group INC | $66.45 | 2019 | |
| Ascendis Pharma Endocrinology INC | $57.90 | 2025 | Yorvipath |
| Ascensia Diabetes Care US INC. | $57.20 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $56.58 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Soleno Therapeutics, INC. | $46.21 | 2025 | Vykat Xr |
| Recordati_rare_diseases_inc. | $42.49 | 2023-2024 | Isturisa, Signifor Lar |
| Insulet Corporation | $40.29 | 2019 | |
| Horizon Therapeutics Plc | $39.08 | 2019-2021 | |
| Becton, Dickinson and Company | $37.11 | 2022 | |
| Cequr Corporation | $35.44 | 2023 | Cequr Simplicity |
| Sequel Med Tech, LLC | $33.37 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $30.01 | 2024 | |
| Amryt Pharma Holdings LTD | $27.23 | 2022 | |
| Alfasigma USA, INC. | $26.56 | 2022 | |
| Exact Sciences Corporation | $25.08 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $20.52 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.11 | 2024 | Crysvita |
| Acella Pharmaceuticals, LLC | $19.84 | 2024 | NP Thyroid 60 |
| Ibsa Pharma INC. | $19.76 | 2022 | |
| Vivus LLC | $19.37 | 2024 | Qsymia |
| Bigfoot Biomedical INC | $18.74 | 2022 | |
| Medtronic Minimed, INC. | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preethi Sridhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.